Atea Pharmaceuticals, Inc. (AVIR)
5.36
-0.09
(-1.65%)
USD |
NASDAQ |
Aug 28, 16:00
5.46
+0.10
(+1.87%)
After-Hours: 20:00
Atea Pharmaceuticals Debt to Equity Ratio : 0.0021 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0021 |
| March 31, 2026 | 0.0027 |
| December 31, 2025 | 0.0031 |
| September 30, 2025 | 0.0033 |
| June 30, 2025 | 0.0034 |
| March 31, 2025 | 0.0035 |
| December 31, 2024 | 0.0037 |
| September 30, 2024 | 0.004 |
| June 30, 2024 | 0.0043 |
| March 31, 2024 | 0.0044 |
| December 31, 2023 | 0.0043 |
| September 30, 2023 | 0.0044 |
| June 30, 2023 | 0.0046 |
| March 31, 2023 | 0.0048 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0049 |
| September 30, 2022 | 0.005 |
| June 30, 2022 | 0.0053 |
| March 31, 2022 | 0.0042 |
| December 31, 2021 | 0.0003 |
| September 30, 2021 | 0.0005 |
| June 30, 2021 | 0.0006 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Filana Therapeutics, Inc. | 0.00 |
| CorMedix, Inc. | 0.315 |
| Eloxx Pharmaceuticals, Inc. | 0.00 |
| Cannabis Global, Inc. | -- |
| Breakthrough Chemistry, Inc. | 0.2335 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 232.28M |
| Total Liabilities (Quarterly) | 28.12M |
| Shareholders Equity (Quarterly) | 204.16M |
| Current Ratio | 8.131 |
| Net Debt Paydown Yield | 0.05% |